Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 54.46

+5.6%

1:50 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2865)	2/9/2001 5:51:30 PM
From: Jibacoa	of 52153

At a recent symposium sponsored by the San Antonio Cancer Institute, Dr. Marc Lippman from Georgetown Univ. presented the results of the 4 years MORE trial, which was a double-blind trial comparing raloxifene with placebo in 7,705 post-menopausal patients with osteoporosis. One outcome of that trial was that raloxifene cut breast cancer risk by 72%. Despite that favorable outcome, Dr. Lippman doesn't endorse prescribing raloxifene for brest cancer prevention.He feels that it should be reserved for the few women that can't tolerate tamoxifen. I guess we will have to way for the outcome of the STAR trial which is a head to head comparison between Lilly's Evista and Astra/Zeneca's Nolvadex for breast cancer prevention. Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next